Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib + Carboplatin + Paclitaxel in Japanese Ovarian Cancer
NCT02483104Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of veliparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by AbbVie Inc. Primary endpoint: Dose-limiting toxicities at 21 days. Started Jul 2015; status: completed.
02
Drugs
veliparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02483104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483104.